PD Treatment Updates in 2023

At the regular February 8, 2023 virtual support group meeting, our guest speaker was:
Gaurav Chattree, MD, movement disorder specialist, Stanford.
He updated attendees about four PD treatments in the clinical study pipepline, and new-ish symptomatic therapies. He briefly addressed focused ultrasound and stem cell therapy for PD. Attendees asked questions about exercise, constipation, incontinence, and impulse control disorder.
Visit the Palo Alto Parkinson's Support Group
med.stanford.edu/parkinsons/n...
Stanford's APDA Information & Referral Center and Stanford Parkinson's Community Outreach coordinate a local Parkinson's Disease (PD) support group in Palo Alto. Since March 2021, we meet virtually, highlighting local resources, Stanford healthcare professionals, and Stanford research.

[@heangsuysiek265]

Thank you very much!

[@isabellefisher8790]

Thank you for the clear and unbiased explanations.

[@nansen3380]

Thank you for your efforts, with this diagnosis the only drug is hope.

[@roryblake7311]

Thanks for the presentation: My personal channel has more on walking to improve symptoms (I'm a clinical pharmacist working in the Microbiome)

[@SandraAnnEvans]

AMAZING!

[@michaeloconnor9465]

Drugs in phase 3 are still 10 years plus away from being approved. Once phase 3 is completed, it can be 4 years before a drug is approved. People with parkinsons don't have 10 years plus. Drugs need to be fast tracked for approval like they do with cancer Drugs.